BridgeMD
New treatment option for Corneal Neovascularization
Official title Corneal Crosslinking for Treatment of Corneal Neovascularization
ClinicalTrials.gov ID: NCT04787471
What this study is testing
What is 30 minute photoactivation of riboflavin 0.1%?
30 minute photoactivation of riboflavin 0.1% is an investigational medicine, being studied as a potential treatment for corneal neovascularization.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- 18 years of age or older
- With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid...
- Signed written informed consent.
You likely can't join if
- Known sensitivity to treatment medications
- Current condition that in the investigator's opinion could compromise safety or data integrity.
- Pregnancy (including plan to become pregnant) or lactation during the course of the study
The study team makes the final eligibility decision.
Where it's taking place
- Indianapolis, Indiana, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Indianapolis, Indiana, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.